Perspective Therapeutics (NYSE:CATX) Earns Buy Rating from Analysts at UBS Group

UBS Group started coverage on shares of Perspective Therapeutics (NYSE:CATX) in a report issued on Thursday morning, MarketBeat.com reports. The firm issued a buy rating and a $20.00 price objective on the stock.

CATX has been the topic of several other reports. Royal Bank of Canada decreased their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research report on Friday, August 16th. Oppenheimer restated an “outperform” rating and set a $22.00 target price on shares of Perspective Therapeutics in a research report on Friday, October 11th. Truist Financial began coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price on the stock. Bank of America began coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 target price on the stock. Finally, Wedbush began coverage on shares of Perspective Therapeutics in a research report on Tuesday, October 1st. They set an “outperform” rating and a $25.00 target price on the stock. Ten analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $20.63.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at $11.53 on Thursday. Perspective Therapeutics has a 52 week low of $2.20 and a 52 week high of $19.05. The business has a fifty day moving average of $13.76.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.53 million during the quarter. As a group, equities analysts expect that Perspective Therapeutics will post -0.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors have recently bought and sold shares of CATX. Janus Henderson Group PLC acquired a new stake in Perspective Therapeutics in the first quarter valued at approximately $15,511,000. Affinity Asset Advisors LLC acquired a new stake in Perspective Therapeutics in the first quarter valued at approximately $6,069,000. Vanguard Group Inc. boosted its stake in Perspective Therapeutics by 34.6% in the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after acquiring an additional 4,566,356 shares in the last quarter. Nicholson Wealth Management Group LLC acquired a new stake in Perspective Therapeutics in the third quarter valued at approximately $21,390,000. Finally, Ally Bridge Group NY LLC acquired a new stake in Perspective Therapeutics in the second quarter valued at approximately $3,951,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.